Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946094927> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2946094927 endingPage "139" @default.
- W2946094927 startingPage "139" @default.
- W2946094927 abstract "RationaleIntracerebral haemorrhage caused ˜3 million deaths worldwide in 2015. Two‐thirds of survivors are left dependent on others. Roughly one third of patients are taking antiplatelet drugs at the time of intracerebral haemorrhage in high‐income countries, and this proportion has been increasing over time. Pre‐stroke antiplatelet drug use is associated with a 27% relative increase in one‐month case fatality compared to patients not using antithrombotic drugs. Platelet transfusion, tranexamic acid, and recombinant activated factor VII do not seem to improve outcome after antiplatelet‐associated intracerebral haemorrhage, but desmopressin has seemed promising in non‐randomised pilot studies.ObjectivesWe aim to assess the feasibility of screening, checking the eligibility, approaching, randomising, administering desmopressin or placebo, and completing follow‐up for patients with antiplatelet‐associated intracerebral haemorrhage. DesignWe aim to include 50 patients within 12 hours of spontaneous intracerebral haemorrhage onset, associated with oral antiplatelet drug(s) use in the preceding seven days. Exclusion criteria are: known secondary cause for intracerebral haemorrhage; risk of fluid retention associated with desmopressin; significant hypotension (SBP < 90 mmHg); known drug‐eluting coronary artery stent in previous three months; allergy to desmopressin; pre‐stroke dependency; Glasgow coma scale < 5; pre‐morbid life expectancy < 3 months; and pregnant or breastfeeding at randomisation. Patients will be randomised (1:1) to receive intravenous desmopressin 20 μg in 50 mls Sodium Chloride 0.9% infused over 20 minutes or matching placebo. We will mask participants, relatives, researchers and outcome assessors to treatment allocation. Feasibility outcomes include proportion of patients approached being randomised, number of patients receiving allocated treatment, rate of recruitment, and adherence to treatment and follow up. Secondary outcomes include change in intracerebral haemorrhage volume at 24 hours; hyponatraemia at 24 hours, length of hospital stay, discharge destination, early mortality < 28 days, death or dependency at day 90, mortality up to day 90, serious adverse events (including thromboembolic events) up to day 90; disability (Barthel index, day 90), quality of life (EuroQol, day 90), cognition (telephone MMSE day 90), and health economic assessment (EQ‐5D). Baseline platelet dysfunction will be measured and correlated with response to desmopressin; and change in factor VIII, VWF antigen and VWF activity will be assessed one hour after administration of desmopressin.ConclusionThis is a feasibility trial, which will inform the design of a definitive trial." @default.
- W2946094927 created "2019-05-29" @default.
- W2946094927 creator A5008681328 @default.
- W2946094927 creator A5010634901 @default.
- W2946094927 creator A5020457925 @default.
- W2946094927 creator A5028686325 @default.
- W2946094927 creator A5041459796 @default.
- W2946094927 creator A5043407054 @default.
- W2946094927 creator A5057729313 @default.
- W2946094927 creator A5057794391 @default.
- W2946094927 creator A5058613657 @default.
- W2946094927 creator A5085913632 @default.
- W2946094927 creator A5087195871 @default.
- W2946094927 date "2019-03-27" @default.
- W2946094927 modified "2023-10-18" @default.
- W2946094927 title "Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial" @default.
- W2946094927 hasPublicationYear "2019" @default.
- W2946094927 type Work @default.
- W2946094927 sameAs 2946094927 @default.
- W2946094927 citedByCount "0" @default.
- W2946094927 crossrefType "journal-article" @default.
- W2946094927 hasAuthorship W2946094927A5008681328 @default.
- W2946094927 hasAuthorship W2946094927A5010634901 @default.
- W2946094927 hasAuthorship W2946094927A5020457925 @default.
- W2946094927 hasAuthorship W2946094927A5028686325 @default.
- W2946094927 hasAuthorship W2946094927A5041459796 @default.
- W2946094927 hasAuthorship W2946094927A5043407054 @default.
- W2946094927 hasAuthorship W2946094927A5057729313 @default.
- W2946094927 hasAuthorship W2946094927A5057794391 @default.
- W2946094927 hasAuthorship W2946094927A5058613657 @default.
- W2946094927 hasAuthorship W2946094927A5085913632 @default.
- W2946094927 hasAuthorship W2946094927A5087195871 @default.
- W2946094927 hasConcept C126322002 @default.
- W2946094927 hasConcept C127413603 @default.
- W2946094927 hasConcept C141071460 @default.
- W2946094927 hasConcept C142724271 @default.
- W2946094927 hasConcept C204787440 @default.
- W2946094927 hasConcept C27081682 @default.
- W2946094927 hasConcept C2778702241 @default.
- W2946094927 hasConcept C2780645631 @default.
- W2946094927 hasConcept C42219234 @default.
- W2946094927 hasConcept C71924100 @default.
- W2946094927 hasConcept C78519656 @default.
- W2946094927 hasConceptScore W2946094927C126322002 @default.
- W2946094927 hasConceptScore W2946094927C127413603 @default.
- W2946094927 hasConceptScore W2946094927C141071460 @default.
- W2946094927 hasConceptScore W2946094927C142724271 @default.
- W2946094927 hasConceptScore W2946094927C204787440 @default.
- W2946094927 hasConceptScore W2946094927C27081682 @default.
- W2946094927 hasConceptScore W2946094927C2778702241 @default.
- W2946094927 hasConceptScore W2946094927C2780645631 @default.
- W2946094927 hasConceptScore W2946094927C42219234 @default.
- W2946094927 hasConceptScore W2946094927C71924100 @default.
- W2946094927 hasConceptScore W2946094927C78519656 @default.
- W2946094927 hasLocation W29460949271 @default.
- W2946094927 hasOpenAccess W2946094927 @default.
- W2946094927 hasPrimaryLocation W29460949271 @default.
- W2946094927 hasRelatedWork W2066288338 @default.
- W2946094927 hasRelatedWork W2091896847 @default.
- W2946094927 hasRelatedWork W2130249111 @default.
- W2946094927 hasRelatedWork W2130729761 @default.
- W2946094927 hasRelatedWork W2183695440 @default.
- W2946094927 hasRelatedWork W2266921627 @default.
- W2946094927 hasRelatedWork W2343894806 @default.
- W2946094927 hasRelatedWork W2574716662 @default.
- W2946094927 hasRelatedWork W2785988877 @default.
- W2946094927 hasRelatedWork W2964529858 @default.
- W2946094927 hasRelatedWork W2997079181 @default.
- W2946094927 hasRelatedWork W3010729818 @default.
- W2946094927 hasRelatedWork W3032488641 @default.
- W2946094927 hasRelatedWork W3036528941 @default.
- W2946094927 hasRelatedWork W3082109096 @default.
- W2946094927 hasRelatedWork W3093824886 @default.
- W2946094927 hasRelatedWork W3102091063 @default.
- W2946094927 hasRelatedWork W3159523592 @default.
- W2946094927 hasRelatedWork W3198285050 @default.
- W2946094927 hasRelatedWork W3206049145 @default.
- W2946094927 hasVolume "185" @default.
- W2946094927 isParatext "false" @default.
- W2946094927 isRetracted "false" @default.
- W2946094927 magId "2946094927" @default.
- W2946094927 workType "article" @default.